DOI: 10.1128/AAC.02225-13
ABSTRACT
Here, we show that spiroindolone, an effective treatment for plasmodia, is also active against Toxoplasma gondii tachyzoites. In vitro, spiroindolone NITD609 is cidal for tachyzoites (50% inhibitory concentration [IC50], 1μM) and not toxic to human cells at ≥10μM. Two daily oral doses of 100 mg/kg of body weight reduced the parasite burden in mice by 90% (P = 0.002), measured 3 days after the last dose. This inhibition of T. gondii tachyzoites in vitro and in vivo indicates that spiroindolone is a promising lead candidate for further medicine development.
FOOTNOTES
- Received 14 October 2013.
- Returned for modification 7 November 2013.
- Accepted 15 December 2013.
- Accepted manuscript posted online 23 December 2013.
Supplemental material for this article may be found at http://dx.doi.org/10.1128/AAC.02225-13.
- Copyright © 2014, American Society for Microbiology. All Rights Reserved.